|
목적 : To evaluate long-term outcome of intravitreal anti-vascular endothelial growth factor (VEGF) monotherapy for patients diagnosed with submacular hemorrhage secondary to exudative age-related macular degeneration (AMD).
방법 : This retrospective, observational study included 49 patients (49 eyes) who initially presented with submacular hemorrhage associated with exudative AMD and were followed-up at least 24 months. Eyes that were treated with intravitreal anti-VEGF monotherapy were included. Best-corrected visual acuity (BCVA) at diagnosis, at 6 months, and at final visit was compared. The association of BCVA at final visit with baseline BCVA, BCVA at 6 months, duration of symptoms, extent of hemorrhage, and central foveal thickness, was additionally analyzed.
결과 : During the mean 32.1 ± 8.5 months of follow-up period, 5.1 ± 2.2 anti-VEGF injections were performed. Recurrent hemorrhage was noted in 13 eyes (26.5%). The mean logarithm of minimal angle of resolution BCVA at diagnosis, at 6 months, and at final visit was 1.40 ± 0.52, 0.87 ± 0.64, and 1.03 ± 0.83, respectively. The BCVA at final visit was significantly improved when compare to the baseline value (P = 0.012), whereas the difference with BCVA at 6 months was not significant (P = 0.156). Both baseline BCVA (P = 0.012) and BCVA at 6 months (P < 0.001) was found to be associated with BCVA
결론 : Improved visual acuity was maintained longer than 2 year period with intravitreal anti-VEGF monotherapy. BCVA at 6 months can be used as a useful clinical index predictive of long-term visual prognosis.
|